海普瑞(09989.HK)持股公司提交有关关键肾保护及血糖控制市场新知识产权申请
海普瑞(09989.HK)公布,公司持有约38.5%股份的Resverlogix宣布根据其重大发现扩大新知识产权申请,即当Apabetalone与钠–葡萄糖协同转运蛋白-2(SGLT2)抑制剂(一类领先的口服抗糖尿病治疗方法)联合用药,可发挥协同作用,显着改善肾功能及血糖控制。
集团指,鉴於BETonMACE3期试验的有关发现超出预期,Resverlogix已提交两项新增临时专利申请,进一步强化其知识产权组合。於心血管健康领域,Apabetalone在单独用药及与SGLT2抑制剂联合用药方面均已拥有获授予及待审核的知识产权。
集团提到,其拥有RVX-208 (Apabetalone)的大中华区独家开发和商业权,认为额外两项新的专利申请将延长候选药物的潜在生命周期,显着提高RVX-208 (Apabetalone)创新疗法的整体价值,并进一步加强於大中华地区的开发和商业化计划。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.